July 12, 2012
Bayer HealthCare of Germany has announced that it has started to enroll patients in the multinational PIII PROTECT VIII trial for its investigational compound BAY94-9027 for the treatment of hemophilia A. The PIII trial will be conducted globally and Japan...read more